Advancing molecular diagnostics to personalize cancer therapyDocument Transcript
Advancing Molecular Diagnostics to Personalize Cancer TherapyIntroductionThis report analyzes current and potential world markets for key cancer-based molecular diagnostics,including advances in the field. This report forecasts future growth to 2016. Market segments coveredinclude: breast cancer; colon cancer; prostate cancer; non-small cell lung cancer; melanoma; and renalcancer. This report reviews the direction of research, and key issues facing the industry.http://www.aarkstore.com/reports/Advancing-Molecular-Diagnostics-to-Personalize-Cancer-Therapy-147511.htmlFeatures and benefits* Identify key innovations in molecular diagnostics for oncology that may compete with those indevelopment at your company.* Understand the regulatory challenges facing the developers of molecular diagnostics for cancer.* Understand the challenges that surround successfully commercializing a combined drug-diagnosticproduct and learn how to overcome them.* Discover and analyze the key technology platforms being used in the development of novel moleculardiagnostics.* Discover the forecast market size for key segments of the cancer diagnostics market including: breast,colorectal, prostate, lung, and renal cancer.HighlightsAdvances in genomics, proteomics, molecular imaging, and other new technologies are leading to amolecularly based reclassification of malignancy, creating market opportunities for diagnosticcompanies.Companion diagnostics - linking drugs with diagnostics - is expected to become the prevailing healthcare model, offering advantages for both the prescription drug and diagnostics businesses. Fordiagnostics companies, combining with a successful companion drug can be a powerful driver of sales,especially when required for prescribing a drug.If government regulatory agencies increase the use of biomarkers and diagnostics in prescribingdecisions, it is likely that drug and diagnostics companies will increase their collaboration. Newrelationships are likely to develop between partners committed to personalized medicine embracing theapproach of specialized pharmaceutical firms.
Your key questions answered* Which of the cancer diagnostic market segments are forecast to grow most rapidly through to 2016and thus be the most commercially attractive?* What are the key innovations in molecular diagnostics that are going to drive market growth?* How can pharma and diagnostic companies work together to successfully develop combined drug anddiagnostic products?* Which companies are developing the most promising technologies?2012 Global Cancer Diagnostics Market Outlook: Growth Opportunities andStrategies2012 World Cancer Diagnostic Market Overview: Facilities, Test Volumes,and Sales Forecasts by Country2012 Germany Cancer Diagnostics Market Outlook: Growth Opportunities andStrategies2012 UK Cancer Diagnostics Market Outlook: Growth Opportunities andStrategies2012 Japan Cancer Diagnostics Market Outlook: Growth Opportunities andStrategiesAarkstore EnterprisePhone: 08149852585Email Id: email@example.comURL: www.aarkstore.comhttp://www.facebook.com/aarkstorehttp://in.linkedin.com/in/aarkstoreKeywords: Advancing, Molecular, Diagnostics, Personalize, Cancer, Therapy, biomarkers, genomics,proteomics, molecular imaging, breast, colorectal, prostate, lung, renal cancer